Lead Product(s): PF1801
Therapeutic Area: Genetic Disease Product Name: PF1801
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: PhaseBio Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Immunoforge is developing agents for rare muscle related diseases, such as Duchenne muscular dystrophy, polymyositis, and inclusion body myositis, based on its patent with PF1801 from PhaseBio, which has completed phase 2 clinical trials.